Plasminogen Activator Inhibitor-1 Signaling Pathway

1. Plasminogen Activator Inhibitor-1 Signaling Pathway Plasminogen activator inhibitor-1 (PAI-1) is a member of the fibrinolytic system plasminogen activator (PA), such as tissue plasminogen activator (t-PA) and urokinase-type fiber, the main physiological inhibitor of lysogen activator (u-PA) is the major regulator of fibrinolytic activity. Studies have shown that PAI-1 has a wide range of effects in various pathological processes such as cardiovascular diseases and tumors. PAI-1 has broad research prospects as a new pharmacological target, and the development of new and highly effective PAI-1 inhibitors has an important research value. Plasminogen activator inhibitor-1 family Plasminogen activator inhibitor (PAI) was first discovered in pregnant women's plasma by Brakman and Astrup in 1963 and has been discovered by other investigators. It has been found that human PAI includes PAI-1, PAI-2, PAI-3 and PAI-4. Among the four PAIs, PAI-1 has 99% activity and plays a major role. PAI-1 is widely distributed in the body's vascular endothelial cells, smooth muscle cells, liver cells, fat cells, macrophages, neutrophils, mesangial cells, platelets and some malignant cells. PAI-1 in plasma is mainly produced by vascular endothelial cells and hepatocytes. PAI-1 is extremely unstable in vitro and in vivo, and its half-life is about 20 min, mainly because its active center of methionine is easily oxidized and PAI-1 is swallowed by binding to t-PA or u-PA to form a complex. There are two main forms of PAI-1 in plasma, one active, called activated PAI-1, and the other inactive, called latent PAI-1. The two forms of PAI-1 have the same molecular weight and immunoreactivity but differ in their configuration. The active PAI-1 can be stabilized and kept active by binding to a cellulose-binding protein. Find more at: https://www.creative-diagnostics.com/plasminogen-activator-inhibitor-1-signaling-p athway.htm